Hepatitis B

Lore & Background

Hepatitis B was originally known as 'serum hepatitis'. Many people have no symptoms after exposure; for others, symptoms may appear 30 to 180 days after exposure and can include nausea, vomiting, yellowish skin, fatigue, yellow urine, and abdominal pain. Symptoms during acute infection typically last for a few weeks, though some may feel sick for up to six months. Deaths from acute stage HBV infections are rare. An HBV infection lasting longer than six months is usually considered chronic. The likelihood of developing chronic hepatitis B is higher for those infected at a younger age: about 90% of those infected during or shortly after birth develop chronic hepatitis B, while less than 10% of those infected after age five develop chronic cases. Most with chronic disease have no symptoms; however, cirrhosis and liver cancer eventually develop in about 25% of those with chronic HBV.

Reader's Guide

Hepatitis B is a significant global health concern, with an estimated 296 million people having chronic infections as of 2019, and 820,000 deaths that year, primarily from cirrhosis and liver cancer. The disease is most prevalent in Africa (7.5% of the population) and the Western Pacific region (5.9%). The virus is 50 to 100 times more infectious than HIV. Since 1982, a highly effective vaccine (98% to 100% effective) has been available, and the World Health Organization recommends infants receive it within 24 hours after birth. National programs have made the vaccine available for infants in 190 countries as of the end of 2021. The WHO has set a goal of eliminating viral hepatitis as a threat to global public health by 2030, which would require developing therapeutic treatments to cure chronic hepatitis B, as well as preventing transmission and using vaccines to prevent new infections.

Did You Know?

• Hepatitis B is 50 to 100 times more infectious than HIV.
• About 90% of those infected during or shortly after birth develop chronic hepatitis B.
• The hepatitis B vaccine has been available since 1982 and is between 98% and 100% effective.
• Cirrhosis and liver cancer are responsible for most HBV-related deaths.

The Silent Threat: Asymptomatic Infection and Chronic Progression

Hepatitis B is deceptively dangerous because it can lurk in the body without warning. Many individuals who encounter the virus never experience a single symptom, making the infection invisible until years later. When symptoms do emerge—typically between 30 and 180 days after exposure—they can strike suddenly with nausea, vomiting, jaundice, fatigue, dark urine, and abdominal discomfort. The acute phase usually resolves within a few weeks, though some patients endure illness for as long as six months. The critical dividing line is that six-month mark: beyond it, the infection is classified as chronic. Age at the time of infection is the single strongest predictor of whether the disease becomes chronic. Infants infected at or near birth face roughly a 90% chance of lifelong infection, while those infected after age five see that risk drop below 10%. Most chronic carriers remain symptomless, yet approximately one in four will eventually develop cirrhosis or liver cancer. The virus has also been linked to conditions beyond the liver, including membranous glomerulonephritis, polyarteritis nodosa, and Gianotti-Crosti syndrome, affecting 1 to 10% of infected individuals.

Transmission and Risk: How the Virus Spreads

The hepatitis B virus travels through infectious blood and body fluids, and the primary routes of acquisition shift dramatically depending on where in the world a person lives. In regions where the disease is endemic, perinatal transmission and childhood blood exposure account for the majority of new infections. In areas where hepatitis B is uncommon, intravenous drug use and sexual contact become the dominant pathways. Healthcare workers, recipients of blood transfusions, patients on dialysis, and individuals living with an infected household member all face elevated risk, as do travelers to high-prevalence countries and those in group living settings. In the 1980s, tattooing and acupuncture were notable contributors to transmission, though improved sterilization practices have since reduced that threat. Importantly, the virus does not spread through casual contact—holding hands, sharing utensils, kissing, hugging, coughing, sneezing, or breastfeeding are all safe. The World Health Organization further recommends screening all donated blood for HBV before transfusion, using antiviral prophylaxis to block mother-to-child transmission, and promoting safe sex practices including condom use as additional layers of protection.

Diagnosis and Treatment: From Detection to Cure

Identifying a hepatitis B infection typically requires a blood test performed 30 to 60 days after exposure, looking for viral components and the body's antibodies against the virus. During the acute phase, medical care is largely supportive, focused on managing the patient's symptoms as the immune system fights the virus. When the infection persists beyond six months and becomes chronic, the treatment landscape shifts to antiviral medications such as tenofovir or interferon, which can help suppress viral replication but remain costly for many patients. For individuals who progress to advanced cirrhosis or develop hepatocellular carcinoma, liver transplantation may become the necessary intervention. Chronic carriers are strongly advised to abstain from alcohol, as its consumption compounds the risk of cirrhosis and liver cancer. Across Europe, hepatitis B and C together account for roughly half of all hepatocellular carcinomas. A small subset of acute cases can escalate to fulminant hepatic failure, a severe and potentially fatal deterioration of liver function. Despite these therapeutic options, a definitive cure for chronic hepatitis B remains elusive, which is precisely why the WHO's 2030 elimination target emphasizes the need for new therapeutic breakthroughs alongside prevention.

Global Burden and the Road to Elimination

The global footprint of hepatitis B is immense. As of 2019, roughly 296 million people—3.8% of the world's population—lived with chronic HBV infection, and 1.5 million more acquired acute infections that year. The death toll stands at 820,000, driven primarily by cirrhosis and liver cancer. Regional variation is striking: Africa bears the heaviest load at 7.5% prevalence, the Western Pacific follows at 5.9%, while Europe and the Americas see 1.5% and 0.5% respectively. Some estimates place the proportion of humanity that has encountered the virus at roughly one-third. The disease was originally termed "serum hepatitis" before its viral cause was confirmed. Since 1982, a vaccine has existed, proving 98% to 100% effective when delivered in the recommended multi-dose course. The WHO advises that infants receive their first dose within 24 hours of birth, and by late 2021, 190 countries had folded the vaccine into national infant immunization schedules. In 2016, the WHO established a 2030 target to eliminate viral hepatitis as a public health threat, a milestone that will demand not only continued vaccination and transmission control but also the creation of curative treatments for those already harboring chronic infection.

Gallery